Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies

Several clinical studies have compared the anti-ischaemic properties of tri metazidine used as monotherapy with those of standard anti-anginal therapy. In the treatment of uncontrolled angina pectoris, the addition of a metabo lic agent such as trimetazidine to existing therapy with a haemodynamic age nt would appear to confer advantages over the addition of a second haemodyn amic agent. Here we report the results of three studies conducted in Poland , the Czech Republic and Hungary that provide additional evidence for the b eneficial effects of combining trimetazidine with a conventional haemodynam ic agent such as P-blockers, long-acting nitrate or calcium channel blocker s. This combination provided significant benefits in terms of improved exer cise capacity and decreased number of angina attacks along with a good tole rability profile. Coron Artery Dis 12 (suppl 1),S25-S280 (C) 2001 Lippincot t Williams and Wilkins.